Pricing Log in Create free account
Saturday 17 October 2026 Export HRMY’s income statement to Excel — free account

Harmony Biosciences Holdings, Inc.

HRMY Healthcare Biotechnology

Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024. In the quarter to June 2026, revenue grew 30.3%, EPS grew 88.4%, free cash flow grew 16.5% and total debt fell 10.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.

38.20 0.07 −0.18%
Market cap
$2.2B
P/E
12.2×
Fwd P/E
9.4×
Dividend yield
—
F-score
5/9
Altman Z
5.23
Beneish M
−2.99
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Harmony Biosciences Holdings, Inc. (HRMY) Business Profile

Updated before January 2025

Company Overview

Harmony Biosciences Holdings, Inc. (HRMY) is a U.S.-based biopharmaceutical company that focuses on developing and commercializing innovative therapies for patients living with rare neurological diseases. Founded in 2017, the company is headquartered in Plymouth Meeting, Pennsylvania. Harmony Biosciences was established with the mission of addressing unmet medical needs in the field of neurology, particularly for conditions that significantly impact patients’ quality of life. The company went public in August 2020, trading on the NASDAQ under the ticker symbol HRMY.

The leadership team at Harmony Biosciences is composed of experienced professionals with extensive backgrounds in the pharmaceutical and biotechnology industries. Key executives include John C. Jacobs, who serves as the President and Chief Executive Officer, and Jeffrey M. Dayno, M.D., the Chief Medical Officer. Their combined expertise has been instrumental in driving the company’s growth and innovation in the biopharmaceutical sector.

Core Business Segments

Harmony Biosciences operates primarily in the biopharmaceutical sector, with a focus on developing therapies for rare neurological disorders. The company’s core business revolves around its flagship product, WAKIX® (pitolisant), and its associated therapeutic applications.

WAKIX® (Pitolisant)

WAKIX® is a first-in-class medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. Unlike traditional stimulant-based therapies, WAKIX® works as a histamine H3 receptor antagonist/inverse agonist, offering a novel mechanism of action. This product has been a cornerstone of Harmony Biosciences’ portfolio and a significant driver of its revenue.

Pipeline Development

In addition to WAKIX®, Harmony Biosciences is actively investing in research and development to expand its product pipeline. The company is exploring the potential of pitolisant in other indications, including idiopathic hypersomnia and other rare neurological conditions. These efforts underscore Harmony’s commitment to addressing unmet medical needs in the neurology space.

Business Model

Harmony Biosciences employs a business model centered on the development, commercialization, and lifecycle management of innovative therapies for rare neurological disorders. The company generates revenue primarily through the sales of WAKIX®, which has seen strong adoption in the U.S. market due to its unique mechanism of action and clinical benefits.

The company’s approach integrates:

  • Research and Development (R&D): Harmony invests heavily in R&D to expand the therapeutic applications of its existing products and to develop new treatments for rare neurological diseases.
  • Commercialization: The company has built a robust sales and marketing infrastructure to support the commercialization of WAKIX® and future products.
  • Patient-Centric Focus: Harmony emphasizes patient education and support programs to ensure that its therapies reach the individuals who need them most.

Strategic Direction

Harmony Biosciences has outlined a clear strategic vision aimed at sustaining growth and expanding its impact in the biopharmaceutical industry. Key elements of the company’s strategic direction include:

  • Pipeline Expansion: Harmony is actively pursuing additional indications for WAKIX® and exploring new therapeutic areas within neurology.
  • Geographic Expansion: The company is evaluating opportunities to expand its presence beyond the U.S. market, potentially entering Europe and other international markets.
  • Sustainability Goals: Harmony is committed to operating responsibly and sustainably, with initiatives aimed at reducing its environmental footprint and supporting community health programs.
  • Partnerships and Collaborations: The company seeks to establish strategic partnerships with other biopharmaceutical firms and research institutions to accelerate innovation and bring new therapies to market.

Competitive Landscape

Harmony Biosciences operates in a competitive biopharmaceutical market, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Jazz Pharmaceuticals: A leader in the sleep disorder market, Jazz offers products such as Xyrem® and Xywav® for narcolepsy treatment.
  • Takeda Pharmaceuticals: Takeda’s portfolio includes treatments for neurological and rare diseases, making it a significant competitor in the space.
  • Avadel Pharmaceuticals: Avadel is developing therapies for sleep disorders, including its investigational drug FT218 for narcolepsy.

Despite the competition, Harmony differentiates itself through its focus on innovative, patient-centric therapies and its commitment to addressing unmet medical needs.

Risk Factors

Like any biopharmaceutical company, Harmony Biosciences faces several risks that could impact its business operations and financial performance. Key risk factors include:

  • Market Dependence: The company relies heavily on the success of WAKIX® for its revenue. Any decline in sales or market acceptance of this product could adversely affect Harmony’s financial performance.
  • Regulatory Risks: The biopharmaceutical industry is highly regulated, and any delays or setbacks in obtaining regulatory approvals for new products or indications could hinder the company’s growth.
  • Supply Chain Disruptions: Harmony depends on third-party manufacturers and suppliers for the production of WAKIX®. Any disruptions in the supply chain could impact product availability.
  • Competition: The presence of established competitors and potential new entrants in the market poses a risk to Harmony’s market share.

Recent Developments

Harmony Biosciences has made significant strides in recent years, including:

  • Expanded Indications for WAKIX®: The company is conducting clinical trials to evaluate the efficacy of WAKIX® in treating idiopathic hypersomnia and other neurological conditions.
  • Corporate Growth: Harmony has expanded its workforce and infrastructure to support its growing operations and pipeline development.
  • COVID-19 Impact: While the pandemic posed challenges for the biopharmaceutical industry, Harmony successfully adapted its operations to ensure the continued availability of WAKIX® and the advancement of its clinical programs.

Investment Considerations

For investors considering Harmony Biosciences, key strengths and risks include:

Strengths

  • Innovative Product Portfolio: WAKIX® offers a unique mechanism of action and addresses significant unmet medical needs.
  • Strong Financial Performance: The company has demonstrated robust revenue growth driven by the success of WAKIX®.
  • Pipeline Potential: Harmony’s ongoing R&D efforts could lead to new revenue streams and market opportunities.

Risks

  • Product Concentration: Heavy reliance on WAKIX® poses a risk if market dynamics change.
  • Regulatory and Competitive Challenges: The biopharmaceutical industry is highly competitive and subject to stringent regulatory requirements.

Conclusion

Harmony Biosciences Holdings, Inc. is a dynamic and growing biopharmaceutical company with a strong focus on addressing unmet medical needs in the field of neurology. With its innovative product portfolio, robust pipeline, and patient-centric approach, Harmony is well-positioned for continued growth. However, investors should carefully consider the risks associated with the company’s reliance on WAKIX® and the competitive landscape. Overall, Harmony Biosciences represents a compelling opportunity in the biopharmaceutical sector, with significant potential for long-term value creation.